A company submitted a Biologics License Application to the FDA.
2 reports, 2 independent
Updated Aug 18
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A company submitted a Biologics License Application to the FDA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
MannKind Corporation
biopharmaceutical company
Related events
- The FDA accepted the Biologics License Application (BLA) under priority review for a drug candidate, apitegromab, developed by Scholar Rock Holding for the treatment of Spinal Muscular Atrophy (SMA).
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
- FDA approval enables commercial opportunity involving CBRE Group.
Coverage
Newest first; wire copies grouped- Insider MonkeyMannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline We recently published 12 Best Healthcare Stocks to Buy Under $30. MannKind Corporation (NASDAQ:MNKD) is one of the best h
- GlobeNewswireMannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update Conference call today at 9:00 am ET 2Q 2025 revenues of $76.5M, +6% v. 2Q 2024 YTD 2025 revenues of $15